• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

    8/19/24 12:12:51 PM ET
    $APDN
    Other Consumer Services
    Consumer Discretionary
    Get the next $APDN alert in real time by email
    SC 13G/A 1 apdn13ga4.txt SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (AMENDMENT NO. 4)* Applied DNA Sciences, Inc. -------------------------------------------------------------------- (Name of Issuer) Common Stock ------------------------------------------------------------------ (Title of Class of Securities) 03815U409 ---------------------------------------------------------------------- (CUSIP Number) 08/19/2024 ---------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this schedule is filed: /X/ Rule 13d-i(b) / / Rule 13d-i(c) / / Rule 13d-i(d) ------------------------ *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act. CUSIP NO. 03815U409 13G/A ------------------------------------------------------------------------ -------- 1 NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) AMH Equity LLC ------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / / (b) / / ------------------------------------------------------------------------ 3 SEC USE ONLY ------------------------------------------------------------------------ 4 CITIZENSHIP OR PLACE OF ORGANIZATION New York, USA ------------------------------------------------------------------------ NUMBER OF 5 SOLE VOTING POWER SHARES 0 BENEFICIALLY -------------------------------------------------- OWNED BY 6 SHARED VOTING POWER EACH ------------------------------------------------- REPORTING 7 SOLE DISPOSITIVE POWER PERSON 0 WITH ------------------------------------------------- 8 SHARED DISPOSITIVE POWER ------------------------------------------------------------------------ 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 shares of common stock. ------------------------------------------------------------------------ 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* / / ------------------------------------------------------------------------ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.00% ------------------------------------------------------------------------ 12 TYPE OF REPORTING PERSON* PN ------------------------------------------------------------------------ CUSIP NO. 03815U409 13G/A ------------------------------------------------------------------------ 1 NAME OF REPORTING PERSON I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Leviticus Partners, L.P. ------------------------------------------------------------------------ 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) / / (b) / / ------------------------------------------------------------------------ 3 SEC USE ONLY ------------------------------------------------------------------------ 4 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware, USA ------------------------------------------------------------------------ NUMBER OF 5 SOLE VOTING POWER SHARES 0 Shares of Common Stock BENEFICIALLY ------------------------------------------ OWNED BY 6 SHARED VOTING POWER EACH ----------------------------------- REPORTING 7 SOLE DISPOSITIVE POWER PERSON 0 Shares of Common Stock WITH --------------------------------------------- 8 SHARED DISPOSITIVE POWER ------------------------------------------------------------------------ 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 0 shares of common stock. ------------------------------------------------------------------------ 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* / / ------------------------------------------------------------------------ 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 0.00% ------------------------------------------------------------------------ 12 TYPE OF REPORTING PERSON* IA ------------------------------------------------------------------------ ITEM 1: (a) NAME OF ISSUER: Applied DNA Sciences, Inc. (b) ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: 50 Health Sciences Drive Stony Brook, New York 11790 ITEM 2: (a) NAME OF PERSON FILING: This Schedule 13G/A is jointly filed by Leviticus Partners, L.P., a Delaware limited partnership ("Leviticus"), and AMH Equity, LLC ("AMH"), a New York limited liability company (each a "Reporting Person" and, collectively, the "Reporting Persons"). AMH is the general partner of Leviticus. (b) ADDRESS OF PRINCIPAL BUSINESS OFFICE : 32 Old Mill Road Great Neck, NY 11023 (c) CITIZENSHIP: See above (d) TITLE OF CLASS OF SECURITIES: SEE COVER PAGE (e) CUSIP NUMBER: SEE COVER PAGE ITEM 3: See Item 12 above ITEM 4: (a) AMOUNT BENEFICIALLY OWNED: See Item 9 above (b) PERCENT OF CLASS: See Item 11 above (c) NUMBER OF SHARES AS TO WHICH SUCH PERSON HAS VOTING AND DISPOSITIVE POWERS: See Items 5 and 7 above ITEM 5: OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS: /X/ ITEM 6: OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON: N/A The principal address of Leviticus is: 32 Old Mill Road Great Neck, NY 11023 ITEM 7: Inapplicable ITEM 8: Inapplicable ITEM 9: NOTICE OF DISSOLUTION OF GROUP: Inapplicable ITEM 10: CERTIFICATION: By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in theordinary course of business and were not acquired and are not held for the purpose of and do not have the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having such purpose or effect. After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. Date: August 19, 2024 Leviticus Partners, L.P. By: AMH Equity, LLC, its general partner By: /s/ Adam Hutt Name: Adam Hutt Title: Managing Member AMH Equity, LLC By: /s/ Adam Hutt Name: Adam Hutt Title: Managing Member
    Get the next $APDN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $APDN

    DatePrice TargetRatingAnalyst
    2/11/2022$8.00 → $6.00Buy
    HC Wainwright & Co.
    8/13/2021$13.00 → $11.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $APDN
    Financials

    Live finance-specific insights

    See more
    • Applied DNA to Report Fourth Quarter and Fiscal Year 2024 Financial Results After Market Close on December 17, 2024; Sets Webcast and Conference Call for January 9, 2025, to Coincide with Update on GMP Manufacturing Facility Build-out

      STONY BROOK, NY / ACCESSWIRE / December 16, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its fourth quarter and fiscal year 2024 financial results after the market close on Tuesday, December 17, 2024.The Company will host a conference call for the investment community to coincide with an update on its GMP manufacturing facility build-out on Thursday, January 9, 2025, at 4:30 p.m. ET.Webcast and Conference Call Date & Time: Thursday, January 9 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402International callers: 412-317-6798Canadian callers

      12/16/24 10:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA to Report Third Quarter Fiscal 2024 Financial Results on Thursday, August 8, 2024

      STONY BROOK, NY / ACCESSWIRE / August 7, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it will release its third quarter fiscal 2024 financial results after market close on Thursday, August 8, 2024. In conjunction with this announcement, Applied DNA management will host a conference call for analysts and members of the investment community starting at 4:30 p.m. ET the same day. On this call, management will discuss the Company's financial results and recent accomplishments.Date & Time: Thursday, August 8 @ 4:30 p.m. ETDial In:Domestic callers (toll free): 844-887-9402Inter

      8/7/24 8:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Announces Second Quarter Fiscal Year 2024 Financial Results

      STONY BROOK, NY / ACCESSWIRE / May 10, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced consolidated financial results for its second fiscal quarter ended March 31, 2024. The Company's Form 10-Q can be viewed at https://investors.adnas.com/sec-filings/. The Company will not host a financial webcast or call for this most recent quarterly reporting period. The Company will host an investor update call on June 12, 2024.Summary Second Quarter Fiscal 2024 Financial Results:Total revenues were approximately $930 thousand for the three-month period March 31, 2024, compared to $4.4 million for the second quarter

      5/10/24 4:05:00 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Applied DNA Sciences Inc.

      SC 13G - APPLIED DNA SCIENCES INC (0000744452) (Subject)

      11/14/24 5:46:25 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

      SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)

      11/13/24 4:15:25 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by Applied DNA Sciences Inc.

      SC 13G/A - APPLIED DNA SCIENCES INC (0000744452) (Subject)

      11/7/24 10:11:34 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Jantzen Beth

      4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

      3/27/23 9:30:56 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • SEC Form 4 filed by Shorrock Clay

      4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

      3/27/23 9:30:40 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • SEC Form 4 filed by Murrah Judith

      4 - APPLIED DNA SCIENCES INC (0000744452) (Issuer)

      3/27/23 9:30:30 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    SEC Filings

    See more
    • Applied DNA Sciences Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)

      6/6/25 2:28:36 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Sciences Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)

      5/29/25 8:15:36 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Sciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - APPLIED DNA SCIENCES INC (0000744452) (Filer)

      5/22/25 4:10:46 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    Leadership Updates

    Live Leadership Updates

    See more
    • Applied DNA Advances Commercialization of Linea(TM) IVT Platform, Appoints Beverly Wolgast as Executive Director of Quality and cGMP Programs

      Experienced Biopharma/Pharmaceutical Executive to Lead Implementation of cGMP-quality LineaDNA™ Capability for IVT mRNA ProductionPreviously Led Manufacturing Operations Scale-up for the BioNTech/Pfizer mRNA COVID-19 Vaccine at CDMO Division of Maravai LifeSciencesSTONY BROOK, NY / ACCESSWIRE / September 6, 2023 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the appointment of Beverly Wolgast, Ph.D., as executive director of Quality and cGMP Programs. Dr. Wolgast will oversee and manage Applied DNA's quality assurance and control and regulatory compliance spanning the Company's three business segments, incl

      9/6/23 9:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Appoints Clay Shorrock as Chief Legal Officer and Executive Director of Business Development

      STONY BROOK, N.Y.--(BUSINESS WIRE)--Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in Polymerase Chain Reaction (PCR)-based DNA manufacturing, today announced that Clay Shorrock, J.D., has rejoined the Company effective immediately to serve on the executive leadership team as Chief Legal Officer and Executive Director, Business Development. In this newly created role, Mr. Shorrock will lead Applied DNA’s legal, regulatory, IP, and business development functions. Dr. James A. Hayward, president and CEO, Applied DNA, said, “As we continue to advance the adoption of our PCR-based, LinearDNATM manufacturing platform across highly regulated markets and further devel

      4/1/21 8:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary

    $APDN
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $APDN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Applied DNA Completes Buildout of GMP Facility for LineaDNA IVT Templates

      - Signals Start of New Commercialization Phase for LineaRx Subsidiary -- Company Negotiating GMP Supply Agreement -- Company Reaffirms Strategic Restructuring Timeline - STONY BROOK, NY / ACCESSWIRE / January 10, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, today announced the completion of the buildout of its new Good Manufacturing Practices (GMP) manufacturing facility (the "facility") within its Stony Brook, New York, headquarters and readiness to accept orders for the manufacture of LineaDNA™ IVT templates that clients can utilize for the production of mRNA clinical trial materials. The facility is undergoing fi

      1/10/25 9:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Reschedules Investor Update Call in Observance of the National Day of Mourning in Recognition of the Passing of Former President Jimmy Carter

      STONY BROOK, NY / ACCESSWIRE / January 8, 2025 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in polymerase chain reaction (PCR)-based technologies, today announced that it has rescheduled its Investor Update call to Thursday, February 13, 2025, to coincide with the release of its first quarter fiscal 2025 financial results.The Company originally scheduled an Investor Update call for January 9, 2025, to update shareholders on its strategic restructuring announced in December 2024 and GMP initiative. The change reflects the observance of the National Day of Mourning in recognition of the passing of former President Jimmy Carter.About Applied DNA Sciences

      1/8/25 4:30:00 PM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • Applied DNA Customer ÚHKT Initiates Phase I Clinical Trial for Rapidly Manufacturable CAR T-Cell Therapy Produced from Linea DNA

      - Regulatory Approval Showcases Clinical Advancement of Linea DNA™ as a Rapid and Effective Means of Producing CAR-T cell Therapies -STONY BROOK, NY / ACCESSWIRE / December 18, 2024 / Applied DNA Sciences, Inc. (NASDAQ:APDN) ("Applied DNA" or the "Company"), a leader in PCR-based DNA technologies, announced that the State Institute for Drug Control of the Czech Republic (SÚKL) approved an application for a Phase I clinical trial of an investigational CD123-specific autologous CAR T-cell therapy by the Institute of Hematology and Blood Transfusion (ÚHKT/Eng: IHBT) in Prague for the treatment of relapsed and/or refractory acute myeloid leukemia (AML). UHKT-CAR123-01 utilizes Applied DNA's synt

      12/18/24 9:00:00 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

      HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $6.00 from $8.00 previously

      2/11/22 6:29:21 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

      HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $11.00 from $13.00 previously

      8/13/21 6:30:16 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary
    • HC Wainwright & Co. reiterated coverage on Applied DNA Sciences with a new price target

      HC Wainwright & Co. reiterated coverage of Applied DNA Sciences with a rating of Buy and set a new price target of $13.00 from $14.00 previously

      4/22/21 6:37:35 AM ET
      $APDN
      Other Consumer Services
      Consumer Discretionary